Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
05
2020
accepted:
15
07
2020
pubmed:
10
8
2020
medline:
11
9
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infection, and pathological hypersecretory conditions. Most PPIs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) into inactive metabolites, and CYP2C19 genotype has been linked to PPI exposure, efficacy, and adverse effects. We summarize the evidence from the literature and provide therapeutic recommendations for PPI prescribing based on CYP2C19 genotype (updates at www.cpicpgx.org). The potential benefits of using CYP2C19 genotype data to guide PPI therapy include (i) identifying patients with genotypes predictive of lower plasma exposure and prescribing them a higher dose that will increase the likelihood of efficacy, and (ii) identifying patients on chronic therapy with genotypes predictive of higher plasma exposure and prescribing them a decreased dose to minimize the risk of toxicity that is associated with long-term PPI use, particularly at higher plasma concentrations.
Identifiants
pubmed: 32770672
doi: 10.1002/cpt.2015
pmc: PMC7868475
mid: NIHMS1629996
doi:
Substances chimiques
Proton Pump Inhibitors
0
CYP2C19 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Types de publication
Guideline
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1417-1423Subventions
Organisme : Burroughs
ID : 1K23DK115827-01A1
Organisme : , and Nutrition Foundation
Organisme : NHGRI NIH HHS
ID : U24 HG010135
Pays : United States
Organisme : Robert Bosch
ID : 1015006
Organisme : NIDDK NIH HHS
ID : K23 DK115827
Pays : United States
Organisme : Hepatology
Organisme : NCATS NIH HHS
ID : UL1 TR001427
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM123930
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010615
Pays : United States
Organisme : North American Society for Pediatric Gastroenterology,
Organisme : NHGRI NIH HHS
ID : U01 HG007269
Pays : United States
Organisme : Fund
ID : 668353
Organisme : Burroughs
ID : 668353
Organisme : NIGMS NIH HHS
ID : R24 GM115264
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121707
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM078501
Pays : United States
Organisme : Wellcome
ID : 668353
Organisme : CANSEARCH foundation
Organisme : EU H2020
Organisme : NHGRI NIH HHS
ID : U01 HG007762
Pays : United States
Informations de copyright
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.
Références
J Clin Pharmacol. 2011 Mar;51(3):333-45
pubmed: 20484619
Med Sci Monit. 2017 Jun 03;23:2701-2707
pubmed: 28577017
Eur J Clin Pharmacol. 2006 Feb;62(2):107-12
pubmed: 16402242
Eur J Pediatr. 2018 Jan;177(1):69-77
pubmed: 29209919
J Korean Med Sci. 2017 May;32(5):729-736
pubmed: 28378544
Br J Clin Pharmacol. 1995 May;39(5):511-8
pubmed: 7669487
Clin Pharmacol Ther. 2002 Jul;72(1):90-9
pubmed: 12152007
Aliment Pharmacol Ther. 2003 Dec;18(11-12):1149-57
pubmed: 14653835
Paediatr Drugs. 2018 Oct;20(5):483-495
pubmed: 30097906
Xenobiotica. 2003 Feb;33(2):211-21
pubmed: 12623762
Clin Pharmacol Ther. 2006 Jan;79(1):103-13
pubmed: 16413245
Curr Gastroenterol Rep. 2008 Dec;10(6):528-34
pubmed: 19006606
Eur Rev Med Pharmacol Sci. 2016 May;20(9):1795-7
pubmed: 27212172
Eur J Clin Pharmacol. 2006 Oct;62(10):877-80
pubmed: 16912869
Am J Gastroenterol. 2010 May;105(5):1046-52
pubmed: 19904250
Clin Pharmacol Ther. 2007 Apr;81(4):521-8
pubmed: 17215846
Ther Adv Drug Saf. 2018 Nov 19;10:2042098618809927
pubmed: 31019676
Clin Pharmacol Ther. 1999 May;65(5):552-61
pubmed: 10340921
Ann Intern Med. 1998 Dec 15;129(12):1027-30
pubmed: 9867757
J Pediatr. 2013 Sep;163(3):686-91
pubmed: 23623526
J Thromb Haemost. 2010 Aug;8(8):1685-93
pubmed: 20492469
Eur J Clin Pharmacol. 2012 Sep;68(9):1267-74
pubmed: 22418828
Clin Pharmacol Ther. 2012 Sep;92(3):388-92
pubmed: 22805424
Hum Mutat. 2019 Nov;40(11):e37-e51
pubmed: 31260137
Contemp Clin Trials. 2019 Mar;78:27-33
pubmed: 30659924
J Gastroenterol Hepatol. 2016 Apr;31(4):716-26
pubmed: 26580676
J Clin Pharmacol. 2008 Nov;48(11):1356-65
pubmed: 18664620
Front Pharmacol. 2017 Sep 22;8:670
pubmed: 29018343
Pediatrics. 2019 Dec;144(6):
pubmed: 31699831
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460
pubmed: 29620484
Eur J Clin Pharmacol. 2005 Jan;60(11):779-84
pubmed: 15578172
Clin Pharmacol Ther. 2001 Mar;69(3):108-13
pubmed: 11240974
Clin Drug Investig. 2012 May 1;32(5):319-32
pubmed: 22455762
J Clin Pharmacol. 2018 Jan;58(1):89-96
pubmed: 28884817
Clin Transl Sci. 2019 Mar;12(2):172-179
pubmed: 30341969
Clin Pharmacokinet. 2002;41(12):913-58
pubmed: 12222994
J Pediatr Gastroenterol Nutr. 2019 Nov;69(5):581-587
pubmed: 31490856